The permanent marketing cessation of the medicinal product MINIRIN/DDAVP 50 mcg/ml nasal spray, solution, AIC 023892033, is planned on October 1, 2025.

The decision by the marketing authorisation holder Ferring is related to its commitment to the CMDh and AIFA in the context of the risk assessment of chlorobutanol, an excipient present in the medicinal product in question.

Minirin/DDAVP 50 mcg/ml nasal spray, solution, AIC 023892033, a medicine containing the active ingredient desmopressin, is indicated for the treatment of: hypopituitary, idiopathic, or symptomatic diabetes insipidus; post-surgical polyuria and polydipsia, reversible or permanent, and for the differential diagnosis of diabetes insipidus and renal function tests.

Healthcare professionals are advised to refer patients to treatment with other desmopressin-based medicines authorized and marketed in Italy in different formulations and with indications similar to those of MINIRIN 50 mcg/ml nasal spray, solution, AIC 023892033, owned by Ferring S.p.A. and other marketing authorisation holders.